BioLineRx is a publicly traded company trading on NASDAQ, led by CEO Ella Sorani.
No upcoming earnings scheduled for BioLineRx
No earnings announcement scheduled
Past 12 earnings reports for BioLineRx
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Q4 2025 | -$0.34Est: -$0.54 | +37.0% | $194.0KEst: $651.6K | -70.2% | — |
| Nov 24, 2025 | Q3 2025 | -$0.22Est: -$0.49 | +55.1% | $427.0KEst: $606.0K | -29.5% | — |
| Aug 14, 2025 | Q2 2025 | -$1.00Est: -$0.46 | -117.4% | $304.0KEst: $608.8K | -50.1% | — |
| May 27, 2025 | Q1 2025 | $0.00Est: -$1.06 | +100.0% | $255.0KEst: $1.5M | -82.8% | — |
| Mar 31, 2025 | Q4 2024 | $0.00Est: $0.00 | — | $11.7MEst: $7.7M | +52.2% | — |
| Nov 25, 2024 | Q3 2024 | -$0.07Est: -$0.10 | +30.0% | $4.9MEst: $4.1M | +20.0% | — |
| Aug 15, 2024 | Q2 2024 | $0.00Est: -$0.14 | +100.0% | $5.4MEst: $3.9M | +37.2% | — |
| May 28, 2024 | Q1 2024 | -$0.01Est: -$0.29 | +96.6% | $6.9M | — | — |
| Mar 26, 2024 | Q4 2023 | -$0.15Est: -$0.22 | +31.8% | $4.8M | — | — |
| Nov 20, 2023 | Q3 2023 | -$0.26Est: -$0.21 | -23.8% | - | — | — |
| Aug 30, 2023 | Q2 2023 | -$0.30 | — | - | — | — |
| May 24, 2023 | Q1 2023 | -$0.10 | — | - | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.